Diffuse Midline Glioma, H3 K27M-Mutant — Trials

Diffuse Midline Glioma, H3 K27M-Mutant — Trials · CancerIndex

Clinical trials

Registered studies

28 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 17
Recruiting: 13
Ph III recruiting: 1
Growth YoY: —
Industry share: 29%
Top sponsor: Ann & Robert H Lurie Children's Hospital of Chicago
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (5)

clinicaltrialsPublishedShowing 1–1 of 1 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05500508	Oral AMXT 1501 Dicaprate in Combination With IV DFMO	terminated	Phase 1 / Phase 2	15	Aminex Therapeutics, Inc.INDUSTRY	2	Dec 24, 2024	clinicaltrials

Data updated 22 days agoSource updated Dec 24, 2024source: clinicaltrials